🇪🇺 Fast delivery (3–5 working days) with GLS ✅ Card or bank transfer 📦 Free shipping from €50
Eloralintide
Eloralintide 10 mg – Selective amylin receptor agonist
Peptology Ltd. · Peptides for weight loss
Eloralintide 10 mg is a selective, long-acting, next-generation amylin receptor agonist. It activates the AMY1–3 receptors independently of GLP-1 and is used in metabolic signaling research.
📦 The product is in our EU warehouse – delivery within 3–5 working days.
125,00 € · In stock
For research use only / Not a medicine
Last updated: 19/10/2026
Eloralintide 10 mg — selective amylin receptor agonist
Eloralintide (CAS 2883634-40-8) is a research peptide from the new generation of amylin analogs. Unlike most molecules in the weight-loss peptides category, it does not act through the GLP-1 receptor but is designed as a selective amylin receptor agonist — the hormonal system that signals to the brain that a meal has ended.
Amylin is co-secreted with insulin from the pancreatic beta cells. The natural hormone, however, degrades within minutes, and its earliest analogs required several injections a day. Eloralintide was developed as a long-acting molecule for once-weekly administration, with preference for the amylin receptor over the calcitonin receptor.
In the Peptology version, Eloralintide is supplied as 10 mg of lyophilized powder in a glass vial, with confirmed purity of 99%+ and intended strictly for research use.
What the vial contains
One vial contains 10 mg of active peptide.
ELORALINTIDE 10 MG
Selective amylin agonist
Long-acting analog with preference for the amylin receptor (AMY) over the calcitonin receptor (CTR).
FORM
Lyophilized powder
Stable in storage prior to reconstitution. Reconstituted with Peptide Matrix Water™ or bacteriostatic water.
Eloralintide is a mono-peptide — unlike combinations such as CS20, the vial contains no GLP-1 component.
Mechanism: amylin receptor signaling without GLP-1
The literature describes several parallel hormonal signaling systems. Incretin peptides (semaglutide, tirzepatide) act through the GLP-1 and GIP receptors. The amylin system is a separate pathway — and this is exactly where Eloralintide acts.
AMYLIN RECEPTOR
Amylin receptors (AMY1–AMY3) are found in the area postrema and brainstem nuclei where AMY1–3 signaling is studied. Eloralintide activates them selectively.
SLOWER GASTRIC EMPTYING
In studies of amylin signaling, gastric emptying and postprandial glucagon are recorded as parameters.
SELECTIVITY
Preference for the amylin receptor over the calcitonin receptor aims for better tolerability compared with non-selective dual agonists (DACRA), at similar efficacy.
Selective versus dual amylin agonist
Cagrilintide is a dual agonist — it activates both the amylin and calcitonin receptors simultaneously (DACRA). Eloralintide follows a different strategy: it concentrates its action on the amylin receptor. The idea is to preserve signaling at the AMY1–3 receptors while limiting the side effects associated with calcitonin signaling.
Pharmacological profile
- Class: selective amylin receptor agonist
- CAS number: 2883634-40-8
- Phase 2 duration: 48 weeks
- Vial content: 10 mg lyophilized peptide
Eloralintide compared with other amylin and incretin analogs
The comparison shows where Eloralintide stands relative to the most-studied molecules in the category.
| Eloralintide | Cagrilintide | Semaglutide | |
|---|---|---|---|
| Hormone family | Amylin | Amylin | Incretin (GLP-1) |
| Receptor profile | Selective amylin | Dual amylin + calcitonin | GLP-1 |
| CAS number | 2883634-40-8 | 1415456-99-3 | 910463-68-2 |
| Highest weight reduction (monotherapy) | up to 20.1% at 48 wks (phase 2) | ~11.5% at 68 wks | ~14.9% at 68 wks |
| In the Peptology catalog | Lyophilized powder · 10 mg · research use only | Lyophilized powder · 5/10 mg · research use only | Lyophilized powder · 5/10 mg · research use only |
The values come from different trials with different durations and populations and do not represent a direct head-to-head comparison.
What the clinical trials show
Eloralintide is one of the fastest-advancing amylin molecules — moving from first human trial to phase 3 in only about two years.
Phase 1 — first human data
In the early trial with repeated weekly dosing, Eloralintide showed a dose-dependent reduction in body weight within 12 weeks, with a tolerability profile dominated by mild gastrointestinal complaints.
Phase 2 — 48 weeks, 263 participants
A randomized, double-blind, placebo-controlled trial in adults with obesity or overweight, published in The Lancet (November 2025). The average change in body weight after 48 weeks was:
| Weekly dose | Weight change | Average, kg |
|---|---|---|
| 1 mg | −9.5% | −10.2 kg |
| 3 mg | −12.4% | −13.3 kg |
| 6 mg | −17.6% | −18.7 kg |
| 9 mg | −20.1% | −21.3 kg |
| 6 → 9 mg (escalation) | −19.9% | −21.0 kg |
| 3 → 6 → 9 mg (escalation) | −16.4% | −17.8 kg |
| Placebo | −0.4% | −0.2 kg |
Phase 3 — the ENLIGHTEN program
Following the phase 2 results, the phase 3 ENLIGHTEN program was launched, studying Eloralintide both as monotherapy and as an add-on to weekly incretin therapy (including in combination with tirzepatide) in people with obesity, with and without type 2 diabetes.
Note: the cited data come from clinical trials of Eloralintide and are presented for scientific-informational purposes. They do not constitute a claim about the effects of the research-grade product sold by Peptology.
Eloralintide by the numbers
- Selective activation of the amylin receptor — AMY1–3 signaling separate from GLP-1
- Up to 20.1% average weight reduction at 48 weeks in phase 2
- Dose-dependent effect — a clear relationship between dose and outcome
- Slower dose escalation reduces gastrointestinal complaints
- Also studied as an add-on to incretin therapy
All figures refer to published clinical data on Eloralintide and are provided for informational purposes.
Regimens used in the trials
Important: this section describes parameters from published clinical protocols of Eloralintide. It is a scientific reference, not a recommendation for individual use, medical advice, or an administration instruction. Research-grade Eloralintide is not an approved drug and is not intended for consumption by humans or animals.
The overall logic of the trials follows the model of other weekly satiety peptides: a low starting dose with gradual escalation to limit gastrointestinal effects.
- Administration: subcutaneous, once weekly
- Maintenance doses tested: 1, 3, 6 and 9 mg weekly
- Escalation: 6 → 9 mg and 3 → 6 → 9 mg regimens
- Observation in the trials: slower escalation is associated with less nausea and fatigue
- Duration: 48 weeks in phase 2
Storage and reconstitution
Eloralintide is supplied as a lyophilized powder. For precise volume and concentration calculations, use the peptide reconstitution calculator.
- Before reconstitution: in a cool, dry place, protected from light; for long-term storage — at 2–8 °C
- After reconstitution with Peptide Matrix Water™: refrigerated at 2–8 °C
- After reconstitution with bacteriostatic water: refrigerated, for about 4 weeks
- Technique: let the diluent run slowly down the wall of the vial, without a direct stream onto the powder
- Homogenizing: gentle swirling, without shaking
Lab tip: a comparison of diluents can be found in the article Bacteriostatic Water versus Peptide Matrix Water.
Frequently asked questions about Eloralintide
What is the difference between Eloralintide and Cagrilintide?
Both are long-acting amylin analogs for once-weekly administration. Cagrilintide is a dual agonist of the amylin and calcitonin receptors, while Eloralintide is designed as a selective amylin agonist.
Is Eloralintide a GLP-1 agonist?
No. Eloralintide acts entirely through the amylin system and does not activate the GLP-1 receptor. That is why it is also being studied as an add-on to incretin peptides.
What results have been reported in the clinical trials?
In phase 2 (48 weeks, 263 participants) the average weight reduction reached 20.1% at 9 mg weekly, versus 0.4% with placebo.
How long does the solution last after reconstitution?
It depends on the diluent. With bacteriostatic water and storage at 2–8 °C, the solution is typically used for about 4 weeks.
Where can I buy Eloralintide for research?
Peptology offers Eloralintide 10 mg with confirmed purity of 99%+ and delivery across Europe — strictly for research purposes.
Related products in the catalog
If you work with Eloralintide, also check out the other peptides studied in metabolic signaling pathways:
Cagrilintide
Dual amylin agonist (DACRA)
CS20
Cagrilintide 10 mg + Semaglutide 10 mg
Semaglutide
GLP-1 receptor agonist
Tirzepatide
Dual GLP-1 / GIP agonist
CS10
Cagrilintide 5 mg + Semaglutide 5 mg
Peptide Matrix Water™
Stabilizing solution for reconstitution
See the full catalog: Peptides for weight loss (GLP-1) · Solutions for peptides · Blog on peptide research
Research warning: Eloralintide 10 mg is offered exclusively for scientific research and in vitro use. It is not a pharmaceutical product and is not an approved drug — Eloralintide remains in clinical development without marketing authorization. The product is not intended for consumption by humans or animals and does not replace medical advice. The clinical trial information cited relates to the Eloralintide molecule and is presented for scientific-informational purposes; it does not constitute a claim about the effects of the research-grade product sold by Peptology.
Molecule identity
| CAS number | 2883634-40-8 |
|---|---|
| Molecular weight | 4526 g/mol |
| Molecular formula | C201H319N49O65S2 |
| Class | Selective amylin receptor agonist |
| Form | Lyophilised powder in a glass vial |
| Storage | Lyophilisate: 2–8 °C, dry and protected from light · after reconstitution: 2–8 °C |
References
- Billings LK et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406:2631–2643.
Laboratory reconstitution
Laboratory protocol — reconstitution, research protocols, storage
Standardized protocol applicable to all research peptides in the Peptology catalogue. To calculate the solution concentration (mg/mL) for each vial, use the peptide reconstitution calculator.
60-second protocol
1. SOLVENT
2. RECONSTITUTION
Add the solvent down the side of the vial, without shaking, wait 10–15 min.
3. CALCULATION
Calculator → concentration mg/mL
4. STORAGE
+2 °C to +8 °C, up to 60 days with Peptide Matrix Water
Quick reference
| Parameter | Value |
|---|---|
| Form | Lyophilized powder |
| Solvent | Peptide Matrix Water |
| Reconstitution volume | 1–3 mL — maximum 3 mL (capacity of the standard vial) |
| Storage before reconstitution | Room temperature, protected from direct light (refrigeration not required) |
| After reconstitution | Up to 60 days at +2 °C to +8 °C with Peptide Matrix Water |
What you need
Precision pipette
Calibrated, 100–1000 µL — for accurately measuring the volume of solvent added to the vial.
70% alcohol swabs
Two swabs — to disinfect the peptide vial and the solvent vial.
Stabilized solvent for lyophilized peptides. Why this one.
Five rules for reconstitution
| ✅ Correct | ❌ Mistake |
|---|---|
| Disinfect the vial caps and the work surface with 70% alcohol; wear gloves | Working without disinfection |
| Add the solvent slowly along the vial wall | Direct jet onto the powder — foaming and denaturation |
| Gentle rolling between the palms | Shaking — foam, which denatures peptides |
| 10–15 minutes waiting at room temperature | Mechanical mixing or heating |
| Visual check: clear, particle-free | Working with a cloudy or discolored solution |
Calculating concentration
⚠️ Maximum 3 mL solvent. The standard vial does not accommodate larger volumes — do not exceed during reconstitution.
- Concentration (mg/mL) = mg in the vial ÷ mL of solvent
- Volume per sample (mL) = amount per sample (mg) ÷ concentration (mg/mL)
- 1 mg/mL = 1 µg/µL · 1 mL = 1000 µL
Reconstitution per vial — solvent: Peptide Matrix Water. Concentration after adding the solvent (1 mg/mL = 1 µg/µL):
| Vial | + 1 mL | + 2 mL | + 3 mL |
|---|---|---|---|
| 10 mg | 10 mg/mL | 5 mg/mL | 3.33 mg/mL |
👉 For any vial and solvent volume — use the calculator. It calculates the concentration (mg/mL, µg/µL) and the volume per sample (mL, µL).
Storage
BEFORE RECONSTITUTION
Room temperature, protected from direct light, in original packaging. Refrigerator not required.
AFTER RECONSTITUTION
+2 °C to +8 °C, up to 60 days with Peptide Matrix Water. Discard any remainder after this period.
FREEZING
Not recommended. Freeze/thaw cycles degrade peptide structure.
Four mistakes to avoid
1. Shaking "to dissolve faster"
Foam = denaturation. Only gentle rolling between the palms.
2. Inappropriate solvent
For peptide stability use only sterile, specially formulated solvent — recommended Peptide Matrix Water.
3. Ignoring slight turbidity
Not fully clear = the sample does not meet the criteria for use.
4. Taking it out of the refrigerator "for an hour–two"
Short exposures add up and compromise stability.
Research status: All Peptology products are intended for laboratory and research use only. They are not medicinal products, not approved for human or veterinary use and do not substitute medical advice. The described protocol is standard laboratory practice for working with lyophilized peptides.
Shipping information
🚚 Shipping information
-
Products in our warehouse – orders placed by 15:00 on working days are dispatched the same day, later orders on the next working day.
-
Delivery with GLS to your address in 3–5 working days.
-
Shipping costs €5 and is free from €50.
Frequently asked questions
Where can I buy Eloralintide in Europe and what does it cost?
You can buy Eloralintide in Europe online from Peptology, from 125,00 €. Delivery with GLS in 3–5 working days. Shipping is free from 50,00 €. Payment by card. Purity 99%+, with an HPLC report for every batch.